Last reviewed · How we verify
clindamycin 1% / benzoyl peroxide 5% tube
clindamycin 1% / benzoyl peroxide 5% tube is a Topical antibiotic combination Small molecule drug developed by Sanofi. It is currently FDA-approved for Acne vulgaris.
Clindamycin kills acne-causing bacteria while benzoyl peroxide reduces sebum production and provides additional antimicrobial and keratolytic effects.
Clindamycin kills acne-causing bacteria while benzoyl peroxide reduces sebum production and provides additional antimicrobial and keratolytic effects. Used for Acne vulgaris.
At a glance
| Generic name | clindamycin 1% / benzoyl peroxide 5% tube |
|---|---|
| Sponsor | Sanofi |
| Drug class | Topical antibiotic combination |
| Target | Bacterial 50S ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, effectively killing Propionibacterium acnes. Benzoyl peroxide is an oxidizing agent that generates reactive oxygen species to kill bacteria and also helps normalize keratinization and reduce sebaceous gland activity. Together, they provide synergistic antibacterial and anti-inflammatory effects for acne treatment.
Approved indications
- Acne vulgaris
Common side effects
- Skin irritation
- Dryness
- Erythema
- Peeling
- Contact dermatitis
Key clinical trials
- A Pilot, Multi-Center, Patient Preference Study Comparing Two Clindamycin/Benzoyl Peroxide Gels. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- clindamycin 1% / benzoyl peroxide 5% tube CI brief — competitive landscape report
- clindamycin 1% / benzoyl peroxide 5% tube updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about clindamycin 1% / benzoyl peroxide 5% tube
What is clindamycin 1% / benzoyl peroxide 5% tube?
How does clindamycin 1% / benzoyl peroxide 5% tube work?
What is clindamycin 1% / benzoyl peroxide 5% tube used for?
Who makes clindamycin 1% / benzoyl peroxide 5% tube?
What drug class is clindamycin 1% / benzoyl peroxide 5% tube in?
What development phase is clindamycin 1% / benzoyl peroxide 5% tube in?
What are the side effects of clindamycin 1% / benzoyl peroxide 5% tube?
What does clindamycin 1% / benzoyl peroxide 5% tube target?
Related
- Drug class: All Topical antibiotic combination drugs
- Target: All drugs targeting Bacterial 50S ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide)
- Manufacturer: Sanofi — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Acne vulgaris
- Compare: clindamycin 1% / benzoyl peroxide 5% tube vs similar drugs
- Pricing: clindamycin 1% / benzoyl peroxide 5% tube cost, discount & access